RELMADA THERAPEUTICS, INC.
NEW YORK, NY · Founded 2012 · CIK 0001553643 · Biotech · Public
Small-molecule therapeutics for oncology and central nervous system disorders
relmada.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $33M
- 7 Form D · Oct 2019
- 84 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 10
- 2 granted · 8 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20132014201520162017201820192020
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $10,694,588 | |
| Private capital raised | Form D · SEC | $6,890,000 | |
| Private capital raised | Form D · SEC | $3,279,998 | |
| Private capital raised | Form D · SEC | $3,414,505 | |
| Private capital raised | Form D · SEC | $8,002,248 | |
| Private capital raised | Form D · SEC | $825,750 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1562 | TROPHOGEN INC | — | — |
| 1563 | Anjon Biologics Inc. | — | — |
| 1564 | STEM PHARM, INCORPORATED | — | — |
| 1565 | RELMADA THERAPEUTICS, INC. | — | $33M |
| 1566 | CELLOLOGI, LLC | — | — |
| 1567 | AUXAGEN, INC. | — | — |
| 1568 | COGNITION THERAPEUTICS, INC. | — | $23M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Shreeram AgharkarDirector
- Douglas BeckExecutive Officer
- Charles CasamentoDirector
- Chuck EnceExecutive Officer
- Paul KellyDirector
- Eliseo SalinasExecutive Officer
- Sandesh SethDirector
- Maged ShenoudaDirector
- Sergio TraversaDirector · Executive Officer
- Ottavio VitoloExecutive Officer
- Nabil YazgiDirector
Patents
- Injectable Suspensionsapplication
- Pharmaceutical Composition Comprising 3-BETA-HYDROXY-5-ALPHA-PREGNAN-20-ONE With Improved Storage And Solubility Propertiesapplication
- Abrasion-resistant Opioid Formulations Which Resist Abuse And Include A Sequestered Opioid Antagonistapplication
- Compositions of (-)-17-(Cyclobutylmethyl)Morphinan-3,14,-Diolgranted
- d-Methadone for the Treatment of Psychiatric Symptomsgranted
- Abrasion-Resistant Opioid Formulationsapplication
- Oral Pharmaceutical Compositions of Buprenorphine and Another Opioid Receptor Agonistapplication
- Abrasion-resistant Opioid Formulationsapplication
- Abrasion-Resistant Opioid Formulations Which Resist Abuse and Include a Sequestered Opioid Antagonistapplication
- Abrasion-resistant Opioid Formulations Which Resist Abuse And Include A Sequestered Opioid Antagonistapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.